Zelah Joel

This inventor holds 14 USPTO granted patents and 10 published patent applications, plus 5 CIPO patents and 11 EPO patents. Top assignees: Cybin UK Ltd, Small Pharma Ltd. Active years: 2022-2026.

USPTO Granted Patents = 14 (Patent Applications = 10)

% Patents Active = 100.0

CIPO Patents = 5 (Patent Applications = 8)

EPO Patents = 11 (Patent Applications = 17)

Average Co-Inventor Count = 5.1

ph-index = 4

Forward Citations = 49(Granted Patents)

Company Filing History:

Years Active: 2022-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12649718 - Synthesis of n,n-dimethyltryptamine-type compounds, methods, and uses preliminary class 548 (2026-06-09),

2. 12521370 - Inhalable formulations (2026-01-13),

3. 12318477 - Injectable and inhalable formulations (2025-06-03),

4. 12251371 - Deuterated or partially deuterated N,N-dimethyltryptamine compounds (2025-03-18),

5. 12157723 - Compounds (2024-12-03),

6. 12084417 - Synthesis of N,N-dimethyltryptamine-type compounds, methods, and uses (2024-09-10),

7. 12076311 - Therapeutic compositions comprising deuterated or partially deuterated N,N-dimethyltryptamine compounds (2024-09-03),

8. 12042564 - Therapeutic solid dosage forms (2024-07-23),

9. 11771681 - Therapeutic compounds (2023-10-03),

10. 11660289 - Deuterated or partially deuterated N,N-dimethyltryptamine compounds (2023-05-30),

11. 11643390 - Synthesis of N,N-dimethyltryptamine-type compounds, methods, and uses (2023-05-09),

12. 11578039 - Compounds (2023-02-14),

13. 11471417 - Deuterated N,N-dimethyltryptamine compounds (2022-10-18),

14. 11377416 - Crystalline forms of hydroxynorketamine (2022-07-05),

Title: Zelah Joel: Innovator in Pharmaceutical Formulations

Introduction

Zelah Joel is a prominent inventor based in London, GB, known for his significant contributions to the field of pharmaceutical formulations. With a total of 14 patents to his name, he has made remarkable strides in developing innovative therapies for psychiatric and neurological disorders.

Latest Patents

Zelah Joel's latest patents include groundbreaking work on injectable and inhalable formulations. These aqueous pharmaceutical formulations consist of a salt of an optionally substituted dimethyltryptamine compound and water, with a pH ranging from 5 to 6.5. The formulations are designed to deliver an effective dose of the compound for use in psychedelic-assisted therapy within a volume of 5 ml or less. They are suitable for both intramuscular injection and nebulized inhalation, demonstrating stability and clinical acceptability. Additionally, he has developed deuterated or partially deuterated N,N-dimethyltryptamine compounds, which offer tailored therapeutic effects for treating psychiatric or neurological disorders.

Career Highlights

Throughout his career, Zelah Joel has worked with notable companies such as Small Pharma Ltd and Cybin UK Ltd. His innovative approaches and dedication to research have positioned him as a key figure in the pharmaceutical industry.

Collaborations

Zelah has collaborated with talented individuals in his field, including Peter Rands and Tiffanie Benway, who have contributed to his research and development efforts.

Conclusion

Zelah Joel's work in pharmaceutical formulations showcases his commitment to advancing therapeutic options for mental health treatment. His innovative patents and collaborations highlight his significant impact on the industry.